查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1808519

内分泌检测市场按类型、产品类型、样本类型、技术、疾病类型和最终用户划分－2025-2030 年全球预测

Endocrine Testing Market by Type, Product Type, Sample Type, Technology, Disease Type, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2024年内分泌检测市场价值将达到100.7亿美元，2025年将成长至108.8亿美元，复合年增长率为8.33%，到2030年将达到162.9亿美元。

主要市场统计数据
预测年份（2024年） 100.7亿美元
基准年（2025年） 108.8亿美元
预测年份（2030年） 162.9亿美元
复合年增长率（%） 8.33%

确定关键驱动因素、新兴创新和市场基本面，将荷尔蒙检测置于现代医疗保健策略的前沿

内分泌检测已成为现代医学的重要支柱，支持多种荷尔蒙失调的诊断和治疗。随着检测灵敏度的提高，以及对内分泌病理生理学理解的不断加深，这些检测已从常规临床工具提升为推动以患者为中心的医疗的策略性槓桿。糖尿病、甲状腺功能障碍和肾上腺疾病等疾病的日益流行，使得精准可靠的诊断方法变得愈加迫切。同时，个人化医疗的发展也对实验室和检测开发人员提出了新的要求，要求他们提供快速、多元且微创的解决方案。

检验由技术突破、监管改革和以患者为中心的护理模式推动的内分泌诊断变革

近年来，在尖端技术创新和监管预期变化的推动下，内分泌诊断领域发生了翻天覆地的变化。串联式质谱质谱和高通量免疫测量融入核心实验室工作流程，将检测准确性和通量释放了新的水平。同时，世界各地的监管机构也推出了更严格的验证要求和品质基准，促使製造商在合规性和文件流程方面投入大量资金。

评估 2025 年美国关税对动态经济中内分泌检测供应链和市场营运的累积影响

2025年，进口试剂、仪器和辅助用品将实施新的关税制度，这使得内分泌检测供应链的韧性成为关注的焦点。实验室和仪器供应商面临着不断上升的投入成本，这促使筹资策略。许多公司正在加速供应商网路的多元化，并建立区域配送中心，以降低成本转嫁和运输延误的风险。

揭示关键细分洞察，展示测试类型、产品类型、样本介质、技术、疾病分类和最终用户如何塑造市场

深入研究市场细分，可以发现支撑内分泌诊断生态系统的检测类型和应用构成了复杂的网路。皮质醇检测仍然是评估肾上腺功能的重要工具，而硫酸脱氢表雄酮检测则已兴起，用于评估肾上腺雄激素的生成。雌二醇检测仍然是生殖健康监测的基石，人类绒毛膜促性腺激素分泌检测则支持不孕症管理和怀孕监测。胰岛素检测对于血糖控制至关重要，性荷尔蒙检测组可以提供全面的内分泌分析，甲状腺刺激素分析是甲状腺疾病管理的基石。

重点介绍美洲、欧洲、中东和非洲地区以及亚太地区的主要区域动态，揭示不同的需求模式、采用率和成长动力

内分泌检测领域的区域动态呈现出显着的多样性，因为营运商需要应对不同的监管环境、报销框架和患者人口结构。在美洲，成熟的报销途径和实验室网路正在促进先进检测平台的快速普及。学术中心与私人企业之间的合作研究计画正在进一步加强创新管道，并使新型诊断方法的试点部署成为可能。

重点介绍影响全球内分泌检测市场的策略联盟、创新组合和竞争进步等关键产业参与者

内分泌诊断领域的主要参与企业正日益努力透过策略联盟、产品组合合理化和技术创新来实现差异化。现有的试剂和仪器供应商正在与生物製药公司合作开发伴随诊断，而诊断专家则正在整合数位健康平台，以简化数据管理和远端监控。

为专注于技术整合、策略伙伴关係和内分泌诊断新兴市场扩张的产业领导者提供可行的建议

产业领导者应采用能够同时进行免疫检测和质谱分析的灵活平台，加速下一代技术的整合。这种整合可以简化工作流程并降低整体拥有成本。同时，与契约製造製造商和区域经销商建立策略伙伴关係可以缓解供应链漏洞，并支援企业快速进入高成长地区市场。

了解我们全面的调查方法：透过一手数据、二手数据和数据三角测量，获得严谨的市场洞察

本次分析采用严格的混合方法研究设计，以确保研究的全面覆盖和严谨的分析。主要见解透过与高阶主管、临床实验室主任、关键意见领袖和采购专家进行结构化访谈收集。这些对话揭示了当前营运挑战、未满足的需求以及整个价值链的策略重点。

观点强调了指导全球内分泌检测发展的策略重点、未来前景和综合创新

内分泌检测市场正处于曲折点，快速的技术进步、不断变化的管理体制以及不断变化的患者期​​望正在汇聚在一起，重新定义诊断范式。細項分析凸显了临床实验室、研究机构和即时诊断 (POC) 提供者的多样化需求，而区域洞察则强调了自适应打入市场策略的重要性。

目录

第一章 引言

第二章分析方法

第三章执行摘要

第四章 市场概况

第五章市场动态

  • 提高对早期发现内分泌失调重要性的认识
  • 扩大就地检验设备的采用
  • 个人化医疗需求不断增长推动客製化内分泌治疗
  • 将人工智慧演算法融入内分泌测试解释以提高诊断准确性
  • 采用多重免疫检测平台同时筛检多种荷尔蒙生物标记物
  • 家用试剂套件的出现，使得在临床环境之外能持续监测激素
  • 建立超灵敏质谱法测定复杂基质中的微量激素
  • 扩大肿瘤学伴随诊断揭示可预测治疗反应的内分泌标记物
  • 加强监管，重点在于检测标准化和品管，提高检测可靠性
  • 增加对穿戴式生物感测器的投资，用于即时荷尔蒙监测和健康管理

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章：美国关税的累积影响（2025年）

第八章内分泌检测市场（按类型）

  • 皮质醇测试
  • 脱氢表雄酮硫酸盐（DHEAS）测试
  • 雌二醇（E2）检测
  • 人类绒毛膜促性腺激素分泌（hCG）检测
  • 胰岛素检测
  • 性荷尔蒙检测
  • 甲状腺刺激素（TSH）检测

第九章内分泌检测市场（依产品类型）

  • 装置
    • 层析法系统
    • 免疫检测分析仪
    • 质谱仪系统
  • 试剂和套件
    • 校准器
    • 控製材料
    • 诊断试剂套件
  • 软体和服务
    • 资讯学解决方案
    • 维护服务

第 10 章内分泌检测市场（依样本类型）

  • 血
  • 唾液
  • 尿

第11章内分泌检测市场（依技术）

  • 临床化学
  • 免疫检测
  • 单株和多株抗体技术
  • 感测器技术
  • 串联式质谱质谱法

第十二章内分泌检测市场（依疾病类型）

  • 肾上腺疾病
    • 爱迪生氏症
    • 库欣氏症候群
  • 糖尿病
  • 性腺疾病
    • 性腺功能低下
    • 卵巢症候群
  • 甲状腺功能障碍
    • 甲状腺功能亢进
    • 甲状腺机能低下症

第十三章内分泌检测市场（依最终用户）

  • 学术机构
  • 诊断实验室
  • 医院和诊所
  • 研究所

14.美国内分泌检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

15. 欧洲、中东和非洲内分泌检测市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

16. 亚太地区内分泌检测市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十七章竞争格局

  • 市场占有率分析（2024年）
  • FPNV定位矩阵（2024年）
  • 竞争分析
    • Bio-Rad Laboratories Inc
    • bioMerieux SA
    • Abbott Laboratories
    • ACON Laboratories, Inc.
    • Agilent Technologies, Inc.
    • BioCheck Inc.
    • Biogenix Inc. Pvt. Ltd
    • Blueprint Genetics Oy
    • Creative Diagnostics
    • Danaher Corporation
    • Diagnostic Automation/Cortez Diagnostics Inc.
    • DiaSorin SpA
    • Eagle Biosciences
    • EKF Diagnostics Holdings Plc
    • Eurofins Analytical Laboratories Inc.
    • Getein Biotech, Inc.
    • Laboratory Corporation of America Holdings
    • MP Biomedicals, LLC
    • Ortho-Clinical Diagnostics, Inc.
    • Quest Diagnostics Incorporated
    • Randox Laboratories Ltd.
    • Shenzhen New Industries Biomedical Engineering Co., Ltd.
    • Siemens Healthcare GmbH
    • Thermo Fisher Scientific Inc.
    • Trivitron Healthcare
    • Eli Science Inc.
    • F. Hoffmann-La Roche Ltd

第十八章 研究人工智慧

第十九章 研究统计

第二十章 研究联络人

第21章 研究报导

第22章 附录

Product Code: MRR-69324464D0E6

The Endocrine Testing Market was valued at USD 10.07 billion in 2024 and is projected to grow to USD 10.88 billion in 2025, with a CAGR of 8.33%, reaching USD 16.29 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 10.07 billion
Estimated Year [2025] USD 10.88 billion
Forecast Year [2030] USD 16.29 billion
CAGR (%) 8.33%

Positioning Hormone Testing at the Forefront of Modern Healthcare Strategies by Highlighting Key Drivers, Emerging Innovations, and Market Foundations

The field of endocrine testing has emerged as a critical pillar of modern healthcare, underpinning the diagnosis and management of a wide array of hormonal disorders. Advances in assay sensitivity, coupled with an expanding understanding of endocrine pathophysiology, have elevated these tests from routine clinical tools to strategic instruments that drive patient-centric care. Increasing prevalence of conditions such as diabetes, thyroid dysfunction, and adrenal disorders has heightened the urgency for precise, reliable diagnostics. At the same time, personalized medicine initiatives are placing new demands on laboratories and test developers to deliver rapid, multiplexed, and minimally invasive solutions.

As regulatory agencies refine guidelines and reimbursement frameworks evolve, manufacturers and laboratories are compelled to reimagine their operational models. Investments in digital health platforms, artificial intelligence for data interpretation, and point-of-care testing are reshaping traditional workflows. This introduction establishes the foundational context for an in-depth exploration of how technological breakthroughs, tariff dynamics, segmentation strategies, regional variations, and competitive intelligence are collectively redefining the endocrine testing landscape.

Examining Transformative Shifts in Endocrine Diagnostics Fueled by Technological Breakthroughs, Regulatory Reforms, and Patient-Centric Care Models

In recent years, the endocrine diagnostics sector has undergone seismic shifts driven by cutting-edge technological innovation and changing regulatory expectations. The integration of tandem mass spectrometry and high-throughput immunoassays into core laboratory workflows has unlocked new levels of assay precision and throughput. Concurrently, regulatory agencies around the world have introduced more stringent validation requirements and quality benchmarks, prompting manufacturers to invest heavily in compliance and documentation processes.

Beyond the bench, patient empowerment and home-based testing models have emerged as transformative forces. Direct-to-consumer test offerings for hormone monitoring and telehealth platforms have blurred the boundaries between clinical settings and at-home care, fostering a more participatory approach to disease management. As laboratories and instrument providers adapt, strategic partnerships with digital health firms and data analytics companies are becoming increasingly commonplace. The confluence of these technological and patient-centric revolutions is redirecting capital flows, reshaping R&D priorities, and setting the stage for an era of highly personalized endocrine care.

Assessing the Cumulative Impact of United States Tariffs on Endocrine Testing Supply Chains and Market Operations throughout 2025 in a Dynamic Economy

The imposition of new tariff structures on imported reagents, instruments, and ancillary supplies in 2025 has cast a spotlight on the resilience of endocrine testing supply chains. Laboratories and instrument vendors have faced elevated input costs, prompting a comprehensive reassessment of procurement strategies. Many organizations are accelerating the diversification of their supplier networks and establishing regional distribution hubs to mitigate the risk of cost pass-through and shipment delays.

In response to these pressures, domestic manufacturers have seized the opportunity to expand production capacities, collaborating with local distributors to ensure continuity of service. End-users have initiated safety-stock buffering plans and negotiated long-term agreements to secure preferential pricing. Although upfront capital expenditures have risen, these strategic adjustments are laying the groundwork for more agile, de-risked operations. Ultimately, the tariff-driven recalibration of supply chains is fostering a renewed emphasis on localization, strategic inventory management, and operational flexibility.

Unveiling Critical Segmentation Insights That Demonstrate How Test Types, Product Categories, Sample Mediums, Technologies, Disease Classifications, and End Users Shape the Market

A deep dive into market segmentation reveals a complex tapestry of test types and applications that underpin the endocrine diagnostics ecosystem. Cortisol assays continue to serve as essential tools for evaluating adrenal function, while dehydroepiandrosterone sulfate testing has gained prominence in assessing adrenal androgen output. Estradiol measurement remains a cornerstone of reproductive health monitoring, and human chorionic gonadotropin testing supports both fertility management and pregnancy surveillance. Insulin assays are indispensable for glycemic control, sex hormone panels provide comprehensive endocrine profiling, and thyroid stimulating hormone analysis is foundational to thyroid disease management.

The instrumentation and consumable landscape is equally multifaceted. Chromatography systems, immunoassay analyzers, and mass spectrometry platforms represent the primary instrument categories driving laboratory modernization. Complementing these instruments, calibrators, control materials, and diagnostic kits enable rigorous quality assurance and assay standardization. Informatics solutions and maintenance services provide the digital infrastructure and technical support necessary to optimize uptime and data integrity.

Sample medium diversity further enriches testing approaches, encompassing blood draws, saliva collection, and urine samples to accommodate both conventional laboratory protocols and emerging at-home testing models. Underlying these modalities, a spectrum of technological platforms-including clinical chemistry, immunoassay, monoclonal and polyclonal antibody technologies, sensor innovations, and tandem mass spectrometry-delivers unparalleled sensitivity, specificity, and throughput.

Disease-centric segmentation highlights distinct demand drivers. The adrenal disorder segment, including Addison's disease and Cushing's syndrome, requires specialized assays for cortisol and adrenal androgens. Diabetes monitoring leverages insulin and related metabolic markers, whereas gonadal disorder evaluation, covering hypogonadism and polycystic ovary syndrome, relies on comprehensive sex hormone panels. Thyroid dysfunction analysis, spanning hyperthyroidism and hypothyroidism, centers on the precise quantification of thyroid stimulating hormone.

Finally, the end-user landscape spans academic institutions pursuing basic research, diagnostic laboratories implementing high-volume workflows, hospitals and clinics integrating point-of-care solutions, and research institutes driving translational discovery. Each segment presents unique operational requirements and strategic priorities, underscoring the importance of tailored solutions and collaboration across the value chain.

Highlighting Key Regional Dynamics across the Americas, Europe Middle East Africa, and Asia Pacific to Reveal Distinct Demand Patterns, Adoption Rates, and Growth Drivers

Regional dynamics within the endocrinology testing sphere exhibit pronounced diversity as operators navigate distinct regulatory landscapes, reimbursement frameworks, and patient demographics. In the Americas, well-established reimbursement pathways and mature laboratory networks facilitate rapid adoption of advanced assay platforms. Collaborative research initiatives between academic centers and commercial entities further bolster innovation pipelines and enable pilot deployments of novel diagnostic modalities.

The Europe, Middle East, and Africa region presents a heterogeneous tapestry of regulatory environments, from the European Union's harmonized directives to varied approval processes across Middle Eastern and African nations. This mosaic compels manufacturers to pursue adaptive market entry strategies, leveraging local partnerships and regulatory expertise. High population growth in certain markets augments demand for cost-effective, point-of-care solutions, while established institutions in Western Europe continue to demand high-precision laboratory instrumentation.

Across Asia-Pacific, rapid economic growth and expanding healthcare infrastructure are driving increased diagnostic investments. In countries with burgeoning middle-class populations, there is notable uptake of minimally invasive and at-home testing options. Governmental initiatives aimed at enhancing rural healthcare access are stimulating deployment of portable immunoassay systems and integrated telehealth platforms. Simultaneously, major regional manufacturers are investing in R&D to develop localized solutions that address endemic endocrine health challenges and align with national healthcare priorities.

Profiling Leading Industry Players to Showcase Strategic Collaborations, Innovation Portfolios, and Competitive Advances Shaping the Global Endocrine Testing Arena

Leading participants in the endocrine diagnostics arena are intensifying efforts to differentiate through strategic alliances, portfolio rationalization, and technological innovation. Established reagent and instrument providers are forging collaborations with biopharmaceutical companies to co-develop companion diagnostics, while diagnostics specialists are integrating digital health platforms to streamline data management and remote monitoring.

In the instrument segment, vendors are focusing on modular designs that accommodate both routine immunoassays and high-resolution mass spectrometry on a unified platform. Reagent manufacturers are prioritizing assay miniaturization and reagent stability to support at-home testing and decentralized laboratory models. Meanwhile, informatics providers are enhancing interoperability, embedding artificial intelligence algorithms for result interpretation, and enabling real-time connectivity across multi-site networks.

Emerging players are capitalizing on niche opportunities by developing sensor-based handheld devices and disposable immunoassay cards tailored for field use. Consolidation activities remain prevalent, as companies seek to expand their geographic footprints and accelerate time to market for innovative assays. This dynamic competitive choreography ensures that strategic investments in R&D, partnerships, and platform extensions will continue to delineate market leadership.

Delivering Actionable Recommendations for Industry Leaders Focused on Technology Integration, Strategic Partnerships, and Emerging Market Expansion in Endocrine Diagnostics

Industry leaders should accelerate integration of next-generation technologies by adopting flexible platforms capable of simultaneous immunoassay and mass spectrometry analyses. Such convergence will streamline workflows and lower total cost of ownership. Concurrently, forging strategic partnerships with contract manufacturers and regional distributors can mitigate supply chain vulnerabilities and support rapid market entry in high-growth territories.

Investing in advanced informatics and artificial intelligence capabilities will enhance diagnostic accuracy and speed decision-making. By deploying cloud-based analytics, organizations can enable remote monitoring, predictive maintenance, and performance benchmarking across multi-site operations. Expanding footprint in emerging markets through localized manufacturing partnerships and regulatory collaborations can unlock new revenue streams and bolster global resilience.

Finally, embracing patient-centric service models, such as direct-to-consumer testing and telehealth integration, will differentiate service offerings and foster deeper engagement. By aligning product roadmaps with evolving reimbursement guidelines and payer expectations, companies can ensure sustained market access and drive long-term adoption across diverse healthcare settings.

Detailing the Comprehensive Research Methodology Employing Primary Interviews, Secondary Analysis, and Data Triangulation to Ensure Rigorous Market Insights

This analysis draws upon a rigorous, mixed-methods research design to ensure comprehensive coverage and analytical precision. Primary insights were gathered through structured interviews with C-suite executives, clinical laboratory directors, key opinion leaders, and procurement specialists. These conversations illuminated current operational challenges, unmet needs, and strategic priorities across the value chain.

Secondary data was meticulously compiled from peer-reviewed journals, regulatory agency publications, patent databases, company annual reports, and trade documentation. Each data point underwent triangulation to validate accuracy and minimize bias. Quantitative information was cross-referenced with historical performance indicators and industry benchmarks, while qualitative findings were synthesized through thematic analysis to identify emergent patterns.

A multi-stage validation process, including peer review by domain experts and technical stakeholders, further enhanced the reliability of the conclusions. Through these integrated research methodologies, the report delivers actionable intelligence that is grounded in empirical evidence and reflective of real-world market dynamics.

Concluding Perspectives Emphasizing Strategic Imperatives, Future Outlook, and Integrative Innovations that Will Guide the Evolution of Endocrine Testing Worldwide

The endocrine testing market stands at an inflection point, where rapid technological advancements, shifting regulatory regimes, and evolving patient expectations converge to redefine diagnostic paradigms. Segmentation analysis underscores the diverse needs of clinical laboratories, research entities, and point-of-care providers, while regional insights highlight the importance of adaptive market entry strategies.

Competitive profiling reveals that success will hinge on the ability to integrate multidisciplinary capabilities-from assay innovation and digital health integration to strategic supply chain partnerships. Actionable recommendations emphasize the need for flexible platforms, robust informatics, and targeted expansion into underserved regions.

As industry stakeholders navigate these complexities, sustained collaboration and a relentless focus on quality, compliance, and patient outcomes will dictate long-term resilience. By leveraging the insights contained herein, decision makers can chart a clear path forward, positioning their organizations to capitalize on the next wave of innovation in endocrine diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Increased awareness of the importance of early detection of endocrine disorders
  • 5.2. Growing adoption of point-of-care testing devices
  • 5.3. Rising demand for personalized medicine approaches driving tailored endocrine therapies
  • 5.4. Integration of artificial intelligence algorithms in endocrine assay interpretation for enhanced diagnostic precision
  • 5.5. Adoption of multiplexed immunoassay platforms for simultaneous screening of multiple hormone biomarkers
  • 5.6. Emergence of home-based endocrine testing kits enabling continuous hormonal monitoring outside clinical settings
  • 5.7. Development of ultra-sensitive mass spectrometry methods for low-abundance hormone quantification in complex matrices
  • 5.8. Expansion of companion diagnostics in oncology revealing endocrine markers predictive of treatment response
  • 5.9. Enhanced regulatory focus on assay standardization and quality control to improve test reliability
  • 5.10. Increasing investment in wearable biosensors for real-time hormonal monitoring and health management

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Endocrine Testing Market, by Type

  • 8.1. Introduction
  • 8.2. Cortisol Test
  • 8.3. Dehydroepiandrosterone Sulfate (DHEAS) Test
  • 8.4. Estradiol (E2) Test
  • 8.5. Human Chorionic Gonadotropin (hCG) Hormone Test
  • 8.6. Insulin Test
  • 8.7. Sex Hormone Tests
  • 8.8. Thyroid Stimulating Hormone (TSH) Test

9. Endocrine Testing Market, by Product Type

  • 9.1. Introduction
  • 9.2. Instruments
    • 9.2.1. Chromatography Systems
    • 9.2.2. Immunoassay Analyzers
    • 9.2.3. Mass Spectrometry Systems
  • 9.3. Reagents & Kits
    • 9.3.1. Calibrators
    • 9.3.2. Control Materials
    • 9.3.3. Diagnostic Kits
  • 9.4. Software And Services
    • 9.4.1. Informatics Solutions
    • 9.4.2. Maintenance Services

10. Endocrine Testing Market, by Sample Type

  • 10.1. Introduction
  • 10.2. Blood
  • 10.3. Saliva
  • 10.4. Urine

11. Endocrine Testing Market, by Technology

  • 11.1. Introduction
  • 11.2. Clinical Chemistry
  • 11.3. Immunoassay
  • 11.4. Monoclonal & Polyclonal Antibody Technologies
  • 11.5. Sensor Technology
  • 11.6. Tandem Mass Spectrometry

12. Endocrine Testing Market, by Disease Type

  • 12.1. Introduction
  • 12.2. Adrenal Disorders
    • 12.2.1. Addison's Disease
    • 12.2.2. Cushing's Syndrome
  • 12.3. Diabetes
  • 12.4. Gonadal Disorders
    • 12.4.1. Hypogonadism
    • 12.4.2. Polycystic Ovary Syndrome
  • 12.5. Thyroid Dysfunction
    • 12.5.1. Hyperthyroidism
    • 12.5.2. Hypothyroidism

13. Endocrine Testing Market, by End User

  • 13.1. Introduction
  • 13.2. Academic Institutions
  • 13.3. Diagnostic Laboratories
  • 13.4. Hospitals & Clinics
  • 13.5. Research Institutes

14. Americas Endocrine Testing Market

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. Argentina

15. Europe, Middle East & Africa Endocrine Testing Market

  • 15.1. Introduction
  • 15.2. United Kingdom
  • 15.3. Germany
  • 15.4. France
  • 15.5. Russia
  • 15.6. Italy
  • 15.7. Spain
  • 15.8. United Arab Emirates
  • 15.9. Saudi Arabia
  • 15.10. South Africa
  • 15.11. Denmark
  • 15.12. Netherlands
  • 15.13. Qatar
  • 15.14. Finland
  • 15.15. Sweden
  • 15.16. Nigeria
  • 15.17. Egypt
  • 15.18. Turkey
  • 15.19. Israel
  • 15.20. Norway
  • 15.21. Poland
  • 15.22. Switzerland

16. Asia-Pacific Endocrine Testing Market

  • 16.1. Introduction
  • 16.2. China
  • 16.3. India
  • 16.4. Japan
  • 16.5. Australia
  • 16.6. South Korea
  • 16.7. Indonesia
  • 16.8. Thailand
  • 16.9. Philippines
  • 16.10. Malaysia
  • 16.11. Singapore
  • 16.12. Vietnam
  • 16.13. Taiwan

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Bio-Rad Laboratories Inc
    • 17.3.2. bioMerieux SA
    • 17.3.3. Abbott Laboratories
    • 17.3.4. ACON Laboratories, Inc.
    • 17.3.5. Agilent Technologies, Inc.
    • 17.3.6. BioCheck Inc.
    • 17.3.7. Biogenix Inc. Pvt. Ltd
    • 17.3.8. Blueprint Genetics Oy
    • 17.3.9. Creative Diagnostics
    • 17.3.10. Danaher Corporation
    • 17.3.11. Diagnostic Automation/Cortez Diagnostics Inc.
    • 17.3.12. DiaSorin S.p.A.
    • 17.3.13. Eagle Biosciences
    • 17.3.14. EKF Diagnostics Holdings Plc
    • 17.3.15. Eurofins Analytical Laboratories Inc.
    • 17.3.16. Getein Biotech, Inc.
    • 17.3.17. Laboratory Corporation of America Holdings
    • 17.3.18. MP Biomedicals, LLC
    • 17.3.19. Ortho-Clinical Diagnostics, Inc.
    • 17.3.20. Quest Diagnostics Incorporated
    • 17.3.21. Randox Laboratories Ltd.
    • 17.3.22. Shenzhen New Industries Biomedical Engineering Co., Ltd.
    • 17.3.23. Siemens Healthcare GmbH
    • 17.3.24. Thermo Fisher Scientific Inc.
    • 17.3.25. Trivitron Healthcare
    • 17.3.26. Eli Science Inc.
    • 17.3.27. F. Hoffmann-La Roche Ltd

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

  • FIGURE 1. ENDOCRINE TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL ENDOCRINE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 20. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC ENDOCRINE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC ENDOCRINE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. ENDOCRINE TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. ENDOCRINE TESTING MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 27. ENDOCRINE TESTING MARKET: RESEARCHAI
  • FIGURE 28. ENDOCRINE TESTING MARKET: RESEARCHSTATISTICS
  • FIGURE 29. ENDOCRINE TESTING MARKET: RESEARCHCONTACTS
  • FIGURE 30. ENDOCRINE TESTING MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. ENDOCRINE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ENDOCRINE TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ENDOCRINE TESTING MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY CORTISOL TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY CORTISOL TEST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY DEHYDROEPIANDROSTERONE SULFATE (DHEAS) TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY DEHYDROEPIANDROSTERONE SULFATE (DHEAS) TEST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY ESTRADIOL (E2) TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY ESTRADIOL (E2) TEST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY HUMAN CHORIONIC GONADOTROPIN (HCG) HORMONE TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY HUMAN CHORIONIC GONADOTROPIN (HCG) HORMONE TEST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY INSULIN TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY INSULIN TEST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SEX HORMONE TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SEX HORMONE TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY THYROID STIMULATING HORMONE (TSH) TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY THYROID STIMULATING HORMONE (TSH) TEST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY MASS SPECTROMETRY SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY MASS SPECTROMETRY SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY CALIBRATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY CALIBRATORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY CONTROL MATERIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY CONTROL MATERIALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY DIAGNOSTIC KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY DIAGNOSTIC KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY INFORMATICS SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY INFORMATICS SOLUTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY MAINTENANCE SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY MAINTENANCE SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY BLOOD, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SALIVA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY URINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY MONOCLONAL & POLYCLONAL ANTIBODY TECHNOLOGIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY MONOCLONAL & POLYCLONAL ANTIBODY TECHNOLOGIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SENSOR TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SENSOR TECHNOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY TANDEM MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY TANDEM MASS SPECTROMETRY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY ADDISON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY ADDISON'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY CUSHING'S SYNDROME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY CUSHING'S SYNDROME, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY DIABETES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY HYPOGONADISM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY HYPOGONADISM, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY POLYCYSTIC OVARY SYNDROME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY POLYCYSTIC OVARY SYNDROME, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY HYPERTHYROIDISM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY HYPERTHYROIDISM, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY HYPOTHYROIDISM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY HYPOTHYROIDISM, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 115. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 117. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 119. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 121. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2030 (USD MILLION)
  • TABLE 123. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 125. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 127. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 129. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 131. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 133. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2025-2030 (USD MILLION)
  • TABLE 135. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 137. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 139. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 141. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 143. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 144. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 145. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 146. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 147. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 148. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2030 (USD MILLION)
  • TABLE 149. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 151. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 152. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 153. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 155. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 156. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 157. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 158. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 159. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2018-2024 (USD MILLION)
  • TABLE 160. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2025-2030 (USD MILLION)
  • TABLE 161. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 163. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 164. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 165. CANADA ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. CANADA ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 167. CANADA ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. CANADA ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 169. CANADA ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 170. CANADA ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 171. CANADA ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 172. CANADA ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 173. CANADA ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 174. CANADA ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2030 (USD MILLION)
  • TABLE 175. CANADA ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. CANADA ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 177. CANADA ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 178. CANADA ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 179. CANADA ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. CANADA ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 181. CANADA ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 182. CANADA ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 183. CANADA ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 184. CANADA ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 185. CANADA ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2018-2024 (USD MILLION)
  • TABLE 186. CANADA ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2025-2030 (USD MILLION)
  • TABLE 187. CANADA ENDOCRINE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. CANADA ENDOCRINE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 189. MEXICO ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. MEXICO ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 191. MEXICO ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. MEXICO ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 193. MEXICO ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 194. MEXICO ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 195. MEXICO ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 196. MEXICO ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 197. MEXICO ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 198. MEXICO ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2030 (USD MILLION)
  • TABLE 199. MEXICO ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. MEXICO ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 201. MEXICO ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 202. MEXICO ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 203. MEXICO ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. MEXICO ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 205. MEXICO ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 206. MEXICO ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 207. MEXICO ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 208. MEXICO ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 209. MEXICO ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2018-2024 (USD MILLION)
  • TABLE 210. MEXICO ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2025-2030 (USD MILLION)
  • TABLE 211. MEXICO ENDOCRINE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. MEXICO ENDOCRINE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 213. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 215. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 217. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 218. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 219. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 220. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 221. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 222. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2030 (USD MILLION)
  • TABLE 223. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 225. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 226. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 227. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 229. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 230. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 231. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 232. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 233. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2018-2024 (USD MILLION)
  • TABLE 234. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2025-2030 (USD MILLION)
  • TABLE 235. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 237. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 239. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 241. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 242. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 243. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 244. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 245. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 246. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2030 (USD MILLION)
  • TABLE 247. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 249. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 250. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 251. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 253. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 254. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 255. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 256. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 257. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2018-2024 (USD MILLION)
  • TABLE 258. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2025-2030 (USD MILLION)
  • TABLE 259. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2030 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2025-2030 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 287. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 289. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 291. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 293. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 295. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 296. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2030 (USD MILLION)
  • TABLE 297. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 299. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 300. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 301. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 303. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 304. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 305. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 306. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 307. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2018-2024 (USD MILLION)
  • TABLE 308. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2025-2030 (USD MILLION)
  • TABLE 309. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 311. GERMANY ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. GERMANY ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 313. GERMANY ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. GERMANY ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 315. GERMANY ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 316. GERMANY ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 317. GERMANY ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 318. GERMANY ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 319. GERMANY ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 320. GERMANY ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2030 (USD MILLION)
  • TABLE 321. GERMANY ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. GERMANY ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 323. GERMANY ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 324. GERMANY ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 325. GERMANY ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 326. GERMANY ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 327. GERMANY ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 328. GERMANY ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 329. GERMANY ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 330. GERMANY ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 331. GERMANY ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2018-2024 (USD MILLION)
  • TABLE 332. GERMANY ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2025-2030 (USD MILLION)
  • TABLE 333. GERMANY ENDOCRINE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. GERMANY ENDOCRINE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 335. FRANCE ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. FRANCE ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)

TA